DA-1726 vs PB-718

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1/glucagon receptor (dual) · full Obesity pipeline

DA-1726

Developed by MetaVia under a licence from Dong-A ST

Phase 1 in Obesitypeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

PB-718

Developed by PegBio

Phase 1/2 in Obesitypeptide
Weak signal

NCT06147544 · Phase 1/2 · completed

The study randomized 36 participants to PB-718 or matched placebo and masked both participants and investigators, but its small sample and safety-focused primary endpoint make it a limited trial for judging clinical benefit. No primary-endpoint results have been posted, so whether the treatment-emergent adverse-event comparison was favorable cannot be determined. Its registered primary outcome on ClinicalTrials.gov is "Incidence of Treatment-Emergent Adverse Events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

No aligned efficacy figure on record for this race.

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDA-1726PB-718
Body weight, % change—Not reported—Not reported
Weight loss of 5% or more—Not reported—Not reported
Weight loss of 10% or more—Not reported—Not reported
Waist circumference, change (cm)—Not reported—Not reported

Body weight, % change

DA-1726
—Not reported
PB-718
—Not reported

Weight loss of 5% or more

DA-1726
—Not reported
PB-718
—Not reported

Weight loss of 10% or more

DA-1726
—Not reported
PB-718
—Not reported

Waist circumference, change (cm)

DA-1726
—Not reported
PB-718
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

DA-1726: no structured comparison results are available for Obesity.

PB-718: no structured comparison results are available for Obesity.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: DA-1726's landscape · PB-718's landscape